triphosphate; CTP, cytidine triphosphate; ATP, adenosine triphosphate; GTP, guanosine triphosphate; NBMPR, nitrobenzyl-thioinosine; TK, tymidine kinase; ADP, adenosine diphosphate; 5NT, 5' nucleotidase; 6MP, 6 mercaptopurine; 6TG, 6-thioguanine; NP, nucleoside phosphorylase; ADA, adenosine deaminase; AP, alkaline phosphatase.
number of factors (reviewed by Whitehouse, 1985) not operative at the cellular level, for example access of the drug to the tumour. In the present paper we review the evidence that nucleoside and nucleobase salvage pathways are an important and often overlooked means of circumventing drug action.
Nucleotide salvage is a mechanism for circumventing antimetabolite action
The majority of currently used anticancer drugs are cytotoxic either by inhibiting DNA synthesis or by damaging the DNA template by alkylation or intercalation. Thus their limited selectivity will be significantly influenced by differences in proliferation rates and nucleotide metabolism between the tumour cells and normal tissues. Based on this premise, over many years Weber and colleagues have investigated differences in nucleic acid metabolism between normal rat liver and hepatoma cells. Their results suggested that the activities of key enzymes controlling anabolic pathways were enhanced whereas those controlling catabolic pathways were diminished in tumour cells. However, since the majority of their experiments were done on whole tissue extracts it is difficult to conclude whether the differences in levels of expression of anabolic enzymes in tumour cells were related to differences in proliferation rates. Subsequently these observations were found to be relevant for human tumours including hepatocarcinoma, renal cell carcinoma, lung neoplasia and leukaemia (Weber, 1983) and formed a basis for a rational approach to the selection of new drugs that would specifically inhibit key enzymes whose activity is enhanced, e.g. the use of tiazofurin to inhibit IMPD (Weber et al., 1988) .
IMP is a key intermediate of purine nucleotide synthesis ( Figure 1 ) as are UMP and TMP in pyrimidine nucleotide synthesis ( Figure 2 ). These metabolites are synthesised by both de novo and salvage pathways and are focal intermediates in the interconversion of nucleotides. The relative contributions of de novo and salvage pathways to the synthesis of these intermediates varies between different tissues. Human lymphocytes (Williams, 1962; Lajtha & Vane, 1958; Scavannec et al., 1982) , bone marrow cells and cells of intestinal and colonic mucosa Leleiko et al., 1983; Mackinnon & Deller, 1973; Saviano & Clifford, 1981) rely very strongly on salvage synthesis and even in leukaemic cells, where de novo synthesis is increased, there is still a 20-fold excess of salvage activity over that of de novo synthesis. Recent work from Weber's group (Natsumeda et al., 1984 (Natsumeda et al., , 1989 has shown that in many other normal tissues and tumours the salvage flux is greater than that of de novo synthesis and furthermore inhibition of de novo synthesis by antitumour agents leads to even higher salvage activity (Natsumeda et al., 1989) . This observation has led to the hypothesis that some forms of unresponsiveness to chemotherapy by inhibitors of de novo synthesis may result, not from any effect of the drug on its target enzyme, but by the circumvention of inhibition via salvage uptake.
If several enzymes of purine metabolism have been noted in both normal and tumour tissue. HPRT activity was elevated relative to normal tissue in the majority of tumour samples (breast and intestine) with levels ranging 0.2-2.0Umg'1.
Nucleoside phosphorylase (NP) and ADA were also raised in tumour tissue whereas AP and 5NT activities were unchanged (Camici et al., 1990) . Although no attempt was made to correlate levels of expression with growth rate or proliferative fraction, the range of values suggests that they may be strongly influenced by some of the mechanisms discussed below.
In studies in this laboratory, in which four different human tumour lines (EJ bladder carcinoma, HOC8 ovarian carcinoma, MCF7 and HDA 231 breast carcinoma) were tested for methotrexate resistance under identical conditions a spectrum of resistance was observed which was unrelated to growth rate and phenotype (Kinsella unpublished observations) .
No detailed molecular mechanism has been proposed to explain the altered balance of de novo and salvage synthesis observed by Weber et (Table I) indicate that there are genes coding for enzymes involved in nucleic acid metabolism on most human chromosomes and in some cases genes coding for enzymes catalysing successive steps are present in the same region of the chromosome e.g. 21q22.1 (Table I ). This and other evidence quoted in Lai et al. (1991) suggests that genes in close physical proximity are co-ordinately regulated. The Ade-D locus of Chinese hamster cells which encodes phosphoribosyl aminoimidazole carboxylase activity and maps to chromosome 4 together with the gene for phosphoribosyl pyrophosphate amidotransferase may be another example of the coalescence of related genetic information and co-ordinate regulation (Barton et al., 1991) . In de novo pyrimidine biosynthesis the first three enzymes also map in the same region of the chromosome 2p22.p2l and form the multifunctional CAD protein.
Other possible regulatory mechanisms include the loss or loss of function of purine responsive elements from the 5' end of the HPRT gene (Walsh et al., 1990) or of other regulatory elements such as those which occur in introns 1 and 2 of the human HPRT gene (Reid et al., 1990) . In addition studies of methylation patterns of many genes have shown that there is an inverse correlation between the level of methylation and gene activity (Feinburg & Volgstein, 1983; Doerfler, 1983; Riggs & Jones, 1983) . In particular specific sites have been identified within and surrounding the mouse and human HPRT genes whose methylation status correlates well with HPRT activity. The region 400bp 3' of exon 1 is extensively methylated in the inactive X chromosome of mouse and humans and completely unmethylated in the active X chromosome (Yen et al., 1986) . A second region of differential methylation has been identified in the 3' 20 Kb of the gene which spans exons 3-9. The sites in this region are completely methylated on the active X and unmethylated on the inactive X (Lock et al., 1986) . Methylation patterns can also be altered by drug exposure. Sites in the 5' region of the hamster TK gene became unmethylated in MNNG induced revertants of TK-cells (Barr et al., 1986) . In addition structural rearrangements, either spontaneous or drug induced, may bring genes into proximity with new regulatory elements which act on gene promotors or may modify the binding of sequence specific regulatory elements by altering chromatin structure.
Support for the circumvention hypothesis comes from the work of Kinsella (1991) in studies of drug-resistance in human embryo fibroblasts of common genetic origin, but exhibiting phenotypes from normal to aggressively tumouri- Kinsella et al. (1990) . Clonogenic measurements made in the presence of foetal bovine serum of the intrinsic sensitivities of these cells to the two. cytotoxic drugs MTX and PALA showed that resistance to both drugs increased with the progression to morphological transformation, anchorage independence and growth in nude mice. The difference in resistance between the immortal and tumourigenic cell lines was eliminated for both drugs when the experiments were repeated in dialysed foetal bovine serum, but could be restored by the addition of hypoxanthine in the case of resistance to MTX and by the addition of uridine in the case of resistance to PALA. No evidence for the presence of amplified DHFR or CAD genes was found in any of these cell lines which was consistent with their lack of stable resistance. These observations suggested an important role for the salvage pathways of purine and pyrimidine biosynthesis in the increased resistance of the more tumourigenic cell lines.
PALA is a powerful inhibitor of de novo pyrimidine biosynthesis whilst MTX, acting on DHFR, inhibits both purine and pyrimidine biosynthesis. Resistance to both drugs is commonly but not always (Kinsella & Fox, 1988) due to amplification, which in the case of resistance to MTX is DHFR (Schimke et al., 1977) and in the case of resistance to PALA, the multi-functional CAD gene (Wahl et al., 1979; Zieg et al., 1983; Meinkoth et al., 1987) . The relationship between gene amplification and tumourigenicity, as assessed by resistance to MTX and PALA has recently been studied in mouse fibrosarcoma (Cillo et al., 1989) and in rat liver cell lines (Otto et al., 1989) exhibiting different degrees of tumourigenicity. In both studies a striking parallel was observed between the acquisition of drug resistance due to gene amplification and increasing tumourigenicity. However, although gene amplification is usually responsible for the high frequency of resistance to these drugs following in vitro selection, amplification of genes mediating drug resistance has been reported in very few tumours (Wright et al., 1990 and refs therein). The ability of cells to salvage nucleosides may facilitate amplification by allowing them to survive long enough for re-replication to occur. However, this is not the mechanism operating in the study of Kinsella (1991) .
These data, although preliminary, support the concept of a progression-linked change in the key metabolic pathways of purine and pyrimidine synthesis (Weber, 1983) . Not surprisingly, inhibitors of de novo pyrimidine synthesis, such as PALA, produce a reduction in the intracellular pyrimidine ribonucleoside (UTP and CTP) and deoxyribonucleoside (dCTP) triphosphate pools (Plagemann & Behrens, 1976; Jayaram et al., 1979; Moyer & Handschumacher, 1979; Moyer et al., 1981; Low & Kufe, 1981) . Moreover, the antiproliferative, cytotoxic and antitumour effects of PALA can be reversed by the addition of exogenous uridine (Johnson, 1977; Cadman & Benz, 1980; Karle et al., 1980; 1984) and partially by deoxycytidine (Bhalla & Grant, 1987) . What all these exogenous agents have in common is that they are either substrates of the salvage pathway enzymes or components of the de novo pathway distal to the inhibitory block.
Plasma levels of nucleic acid components If the circumvention hypothesis is to have any validity for the clinical situation then we must ask whether purines and pyrimidines are present in the plasma in sufficient concentrations to compete with achievable plasma concentrations of drug analogues. Typical of the base analogues used in therapy is 6MP for which plasma concentrations of 10 M and -0.1 l.M were achieved immediately after oral and intravenous administration respectively, but these levels declined rapidly over the subsequent 6 h (Zimm et al., 1984) . Intravenous infusion over 48 h resulted in the maintenance of a mean plasma concentration of 6.9 tM without host toxicity (Zimm et al., 1985) . In comparison, median values (gM) of adenosine, inosine and hypoxanthine in plasma from seven normal individuals at rest were 0.2, 0.6 and 1.3 respectively (Sinkeler et al., 1986) . Plasma hypoxanthine levels were reported for 16 normal subjects (range 0.2-1.9 1LM, mean 0.561gM), ten untreated leukaemia patients (0.1-1.1 #1M, mean 0.68gM) and 14 solid tumour patients (0.3-2.6tEM, mean 0.89 tiM) (Wong & Howell, 1984) . Thus plasma hypoxanthine levels varied over a 10-fold range in both normal and cancer bearing individuals. Plasma adenosine levels in venous and arterial blood were reported at 0.15 ± 0.03 ylM (n = 15) respectively (Solleri et al., 1987) .
Even higher concentrations of nucleotides are present in human plasma. It is generally accepted that concentrations of adenine nucleotides are about 20-30 #AM (Gordon, 1985) .
Other determinations of adenine nucleotides (ATP + ADP + AMP) using HPLC have indicated concentrations ranging from 2-35 jAM (Brankiewicz, personal communication) .
High local concentrations of nucleotides and nucleosides will occur as a result of destruction of tumour cells by cytotoxic therapy. In addition, extracellular ATP concentrations of >50 jLM make erythrocytes semipermeable so that they release more ATP from their cytoplasm. ATP is also released from erythrocytes and platelets as a result of traumatic shock and during inflammatory reactions, at concentrations ranging between 200 ,UM and 1 mM (Gordon, 1985) .
Ecto-enzyme cascade generates nucleosides Nucleosides can be derived from these sources by extracellular nucleotidases present in serum and by ectoenzymes bound to the external face of the plasma membrane ( Figure  3 ). Thus ecto-ATPase, ecto-ADPase, ecto-ADP kinase and 5' nucleotidase, present on a variety of cell types (Boyle et al., 1989; Gutensohn & Rieger, 1986) , enable the conversion of nucleosidetriphosphates (principally ATP, but also GTP, UTP and CTP at lower rates) to their respective nucleosides. Plasma nucleotide concentrations will, therefore, represent a balance between release of nucleotides and their degradation by extracellular nucleotidases. Thus is would appear that sufficient concentrations of nucleosides are likely to be available in vivo to produce significant rescuing effects during drug-induced cytotoxicity.
Nucleoside transporters control influx and efflux
The uptake of nucleosides resulting from ectoenzyme activities is mediated by nucleoside transporters (Cass et al., 1987) . Non-concentrative, facilitated diffusion of a broad range of purine and pyrimidine nucleosides is controlled by kinetically symmetrical transporters which fall in two classes with respect to their sensitivity to inhibition by NBMPR, dilazep and dipyridamole. Sensitive transporters possess high affinity sites for binding NBMPR which inhibits their activity in nanomolar amounts. Resistant transporters lack the high affinity site and are only inhibited by NBMPR at concentrations above 1-10 micromolar. These also possess a broad specificity but their affinity for some nucleosides may differ from that of the sensitive transporters. The properties of the transporter proteins have been reviewed (Plagemann et al., 1988) .
Many cells, including the Morris 3924A rat hepatoma used in several of the studies by Weber and coworkers, express both forms of transporter and there is genetic evidence from mouse S49 (Cohen et al., 1985; Aronow et al., 1985) and L1210 cells (Belt & Noel, 1988) Paterson et al., 1987) .
Active transport of nucleosides has been observed in epithelial cells of rat (Jakobs & Paterson, 1986 ) and rabbit intestine (Jarvis, 1989a) and rat kidney (Le Hir & Dubrach, 1985) , murine splenocytes (Plagemann & Woffendin, 1989) and guinea pig enterocytes (Schwenk et al., 1984 Beck & tJllman, 1989) . A recent overall review of transport systems was provided by Jarvis (1989b) .
Because different tissues vary in the types of nucleoside transporter they express, the cytotoxicity of nucleoside drugs can be abrogated to a greater or lesser extent by NBMPR, dilazep and dipyridamole, a feature that has suggested the possibility of selective protection of normal tissues by inhibitors. Thus Kaplinsky et al. (1986) found that NBMPR protected normal tissues but not NBMPRr neuroblastoma cells against tubericidin (7-deazaadenosine). A similar strategy has been suggested for protecting highly sensitive bone marrow cells when using tubericidin to treat inhibitor resistant leukaemia (Cass, 1989) .
The finding that the cytotoxicity of some nucleoside drugs can be reduced by transport inhibitors while that of others is unaffected indicates that different drugs may use various transporters that have different nucleoside specificities. Prus et al. (1990) found that transport inhibitors reduced the cytotoxicity of tubericidin to MOLT 4 and CCRF CEM T cell lymphoblastic leukaemia cell lines but had no effect on the cytotoxicity of 9-p-D-arabino-furanosylguanine (araG) on the cells.
A three component pathway mediates reutilisation of nucleotides
The salvage of nucleosides and nucleobases can thus be viewed as a three component system comprising the ectoenzyme cascade, carrier mediated transport across the plasma membrane followed by intracellular phosphorylation or phosphoribosylation by kinases, e.g. thymidine kinase (TK) or by phosphoribosyltransferases specific for hypoxanthine and guanine (HPRT) and adenine (APRT).
The kinetic properties of these components are such as to generate very effective salvage systems. Extracellular nucleotidases are especially active in endothelial cells, smooth muscle cells, B lymphoblasts and platelets. The Km value for pig aorta endothelial cell 5NT was 28 ytm (Gordon, 1985) and the apparent Km for human fibroblasts was 38 nM per 106 cells (Boyle et al., 1989) . Apparent Km values of the lymphoblastoid cell line BHG-83-1 for ATPase and ADPase were 20 JM and 50 JAM respectively (Gutensohn & Rieger, 1986) .
The Km values of nucleoside transporters for a number of drug analogues are known to be of the same order of magnitude as those for their normal substrates, e.g. adenosine 50-150 gM, tubericidin 50-120 JM; thymidine 150-250 gM, 5-iodo-2-deoxyuridine 90 JM. Both 6-thioguanine and 6-mercaptopurine are efficiently transported by the hypoxanthine carrier (Km 200-400 lAM) whereas 8-azaguanine differs in that it diffuses through the membrane in its non-ionised form (pK. 6.6) (Plagemann et al., 1981) . 5-Flourouracil is as efficiently transported by the uracil carrier as is uracil (Km 15 mM) but again only in its non-ionised form (pKa 8.0) (Wohlhueter et al., 1980) . Phosphorylation or phosphoribosylation involves high affinity reactions with Km values between 1-1I100M. The Km values of HPRT for the natural substrates hypoxanthine and guanine are similar to those for the cytotoxic analogues 6TG and 6MP (Table II) . Some variation is seen between values for different cell types and between species. Only one study however (Kong & Parks, 1974) was on purified enzyme, where the Km was shown to depend on pH.
Several additional lines of evidence indicate the biological importance of the ecto-enzyme/nucleoside transporter/intracellular phosphorylation route for purine and pyrimidine salvage and by-pass of drug cytotoxicity.
(1) IMP prevented cytotoxicity caused by MTX in B lymphoblastoid cells only if they expressed 5' nucleotidase (5NT) (Thompson, 1986) . (2) The growth inhibitory effects of high concentrations (> 50 JAM) of ATP, ADP, AMP and adenosine on mouse 3T6 cells were prevented by inhibitors of adenosine transport, dipyridamole and NBMPR (Weisman et al., 1988) . (3) Inhibition of de novo purine and pyrimidine synthesis by acivicin caused cytotoxicity which was synergistically enhanced by dipyridamole (Weber, 1983; Fisher et al., 1984) .
Synergistic effects of dipyridamole suggest salvage pathway involvement
In cancer therapy the mechanism of action of dipyridamole (DPM, persantin) is primarily through inhibition of nucleoside transporters, however in interpreting its synergistic effects on cancer chemotherapy other mechanisms may also operate and must be born in mind (Figure 3 ). Since its introduction in 1959 DPM has become widely used in the treatment of cardiovascular disease because it prevents platelet aggregation, has vasodilatory activity and is nontoxic (Fitzgerald, 1987) . The mechanism of inhibition of platelet aggregation was thought to involve inhibition of platelet cyclic AMP phosphodiesterase, however this effect is rather weak and recently the elevation of plasma adenosine by blockage of erythrocyte nucleoside transporters has been proposed (Luthje, 1989) . The adenosine then binds to specific receptors on the platelet surface, causing activation of adenylate cyclase and elevation of cyclic AMP levels associated with inhibition of platelet function. There are also reports that DPM alters plasma membrane properties (SowemimoCoker et al., 1983; Verscheuruen et al., 1983) , potentiates the inhibition of virus replication (Szebeni et al., 1989) and induces interferon (Galabov & Mastikova, 1982) . Whilst it is possible that some of these effects are secondary to inhibition of nucleoside transport, there are clear indications from the above examples that DPM also affects other cellular pro- (1973) cesses. For this reason potentiation by DPM (and probably NBMPR and dilazap also) should only be taken as a first indication of the involvement of nucleoside transport in a process and should be supported by biochemical data.
Since DPM inhibits kinetically symmetrical non-concentrative nucleoside transporters as well as the sodium-dependent concentrative transporters, it may be expected to inhibit both influx and efflux of nucleosides. Sometimes these functions appear to be selectively used by different molecules. Thus DPM prevents repletion of intracellular nucleotide pools by blocking influx of normal nucleosides and can also prevent efflux of fluorodeoxyuridine which leads to elevation of fluorodeoxyuridine monophosphate and the consequent inhibition of thymidylate synthase as a means of enhancing the cytotoxicity of 5FU (Grem & Fisher, 1985; Alberts et al., 1987) . This rationale formed the basis of phase I trial of DPM with 5FU and folinic acid (Budd et al., 1990) . A confounding factor with such treatments in vivo is the presence in blood of proteins, principally al-acid glycoprotein, which bind most of the DPM. The variable concentration of al-acid glycoprotein in different individuals may represent a pharmacogenetic component of drug resistance (Piafsy & Borga, 1977) .
Thymidylate synthase is also inhibited by the quinazolene antifolate, CB3717, which caused growth inhibition of A549 human lung carcinoma cells that could be overcome by salvage of exogenous thymidine (Curtin & Harris, 1988 (Kessel & Dodd, 1972) . DPM inhibited the uptake of thymidine by sarcoma 180 cells but also inhibited the efflux of methotrexate (Cabral et al., 1984; Nelson & Drake, 1984) . Sarcoma 180 was also used with Hela cells to investigate the potentiation of adriamycin toxicity by DPM (Kusumoto et al., 1988 (Howell et al., 1987) , etoposide (VP-16) (Howell et al., 1989a,b) doxorubicin and vinblastine (Howell et al., 1989b There are also numerous other examples, Grem and Fisher (1985) , Nelson and Drake (1984) , Fisher et al. (1984) , Cabral et al. (1984) , Sobreso et al. (1985) and Chan et al. (1989) , of the sensitisation of cells to the cytotoxic effects of MTX, PALA and fluorouridine by nucleoside transport inhibitors and of the rescue from 5-fluorouracil toxicity by uridine.
Resistance to 6-mercaptopurine is multifactorial
The ecto-and cytosolic forms of NT, may be involved in drug resistance in different ways. The ecto form participates in the ecto-enzyme/nucleoside transporter system that recycles normal nucleotides which compete with toxic analogues, whereas the cytosolic enzyme may participate in the dephosphorylation of toxic nucleotides. These alternatives were offered as explanations (Pieters & Veerman, 1988) of the observation that children with common-ALL showed a higher probability of complete remission if the leukaemic cells were NT-than if they were NT+ (Veerman et al., 1985) . The maintenance therapy involved the use of 6-mercaptopurine and MTX.
Levels of thioguanine nucleotides (TGN), the major cytotoxic metabolites of 6MP varied 6.6-fold when measured in erythrocytes of 120 children with ALL (Lennard & Lilleyman, 1989) . Treatment success was correlated with the attainment of high TGN levels, hence factors such as catabolic pathways that reduce TGN levels will contribute to poorer survival. Catabolism occurs via thiopurine methyltransferase (TPMT) to 6-methyl mercaptopurine, via xanthine oxidase to 6-thiouric acid (Lennard & Lilleyman, 1987) and potentially through dephosphorylation mediated by cytosolic NT (Pieters et al., 1987) .
As described by Lennard and Lilleyman (1989) , 6MP is subject to first pass detoxification through the intestine and liver by xanthine oxidase (XO). Although inter-individual variation in expression of this enzyme in tissues is not significant, there may be considerable variation in the amount of XO consumed in food as a consequence of differences in diet. On the other hand, TPMT shows monogenic inheritance of two co-dominantly expressed alleles, TPMTL and TPMTH, controlling low and high levels of activity in erythrocytes and lymphocytes (Weinshilboum & Sladek, 1980; Van Loon & Weinshilboum, 1982) . Individuals homozygous for L/L occur at a frequency of 1 in 300 and 10% of the population is heterozygous (L/H).
Variations in NT activity are found within blood lymphocytes where expression is associated with differentiation and in leukaemias which appear to reflect blockages in differentiation. Thus 'differentiation-arrested' leukaemias such as T acute lymphoblastic leukaemia have low NT activity, whereas 'end cell' leukaemias such as common acute lymphoblastic leukaemia have high NT activity (Gutensohn et al., 1984) . However there is a caveat that these correlations have generally been made by assaying ecto-rather than cytosolic-NT activity. Although Boyle et al. (1989) could find no evidence for separate genes encoding the two forms of NT in fibroblasts they only assayed for the 'low Km' activity described by Spychala et al. (1988 (Bontemps et al., 1989) and is inhibited by Pi. Thus the 'low Km' enzyme has properties similar to those of ecto-NT but those of the 'high Km' enzyme appear to be distinct. Among other tissues the 'high Km' enzyme is found in human lymphocytes, but it is not known yet which of the soluble activities show a preference for TGN or how they are expressed during lymphocyte differentiation.
A further major determinant of the response to MTX and 6MP therapy is the availability of PRPP. Methotrexate causes inhibition of de novo synthesis and results in increased PRPP availability. The increased PRPP levels can then be used for enhanced incorporation of 6MP. Molt 4 (T) Raji (B) and KM3 (non T non B) human lymphoblastoid cells have been compared with respect to the activities of purine de novo (PDNS) and salvage pathways. Molt 4 showed high activity of both pathways, Raji had low PDNS and an active salvage whereas both pathways were moderately active in KM3. The time course of elevation of PRPP levels was measured after MTX exposure (0.02ytM and 0.2 ilM) in all three lines and the amount of hypoxanthine and 6MP incorporated was shown to be directly correlated at each time point with the PRPP level. The absolute amount of 6MP incorporated correlated with the activity of the purine salvage pathway. Overall the data indicate that Raji and Molt 4 cells will be more sensitive to the cytotoxic effect of MTX plus 6MP than KM3 cells (Bokkerink et al., 1988a,b) .
Perspectives
In this review we have cited evidence in support of the hypothesis that salvage of nucleotides involving an ectoenzyme cascade, nucleoside transport and endogenous phosphorylation is a significant mechanism in resistance to a whole variety of antitumour agents. The underlying mechanism is the circumvention of the inhibition of key enzymes of de novo purine or pyrimidine synthesis as proposed by Natsumeda et al. (1989) on biochemical grounds. Our own quoted data (Kinsella, 1991) provide biological support for the idea and in this review we have emphasised the contribution of ecto-enzymes to the process. There is ample evidence that nucleosides are present in serum at concentrations sufficient to fulfill a salvage function and may be augmented locally from the nucleic acids of dying cells in a tumour. The ecto-enzymes involved in the nucleotide cascade are highly active at the observed physiological concentrations of nucleotides. As the genes involved in salvage and de novo synthesis are cloned into expression vectors, their transfection into non-expressing recipient cells offers a powerful means of testing the details and implications of the hypothesis. Salvage pathways appear to be particularly important in leukocytes, where deficiencies of adenosine deaminase, purine nucleoside phosphorylase and 5' nucleotidase appear to be associated with suppression of immunological function. Similar deficiencies occur in some leukaemias and their investigation and correction by genetic engineering promises to illuminate our understanding of the role of salvage not only in drug resistance but also in the wider aspects of leucocyte differentiation and leukaemogenesis.
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